PUBLISHER: Azoth Analytics | PRODUCT CODE: 1420120
PUBLISHER: Azoth Analytics | PRODUCT CODE: 1420120
Azoth Analytics has released a research report titled "Global Therapeutic Antibody Market (2023 Edition)" which provides a complete analysis of the Global Therapeutic Antibody industry in terms of market segmentation By Product Type (Monoclonal Antibody, Bispecific Antibody, Antibody Drug Conjugates, Others), By Source (Fully Human, Humanized, Others), By Application (Oncology, Autoimmune, Infectious disease, Others), By Region and by Country for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.
The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, South Korea, India). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.
The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.
The Global Therapeutic Antibody Market is expected to generate USD 428.20 billion by the end of 2029, up from USD 211.2 billion in 2022. A favourable growth element for the global Therapeutic Antibody market is propelled by the increasing prevalence of chronic diseases, advancements in biotechnology, and the potential for personalized medicine. During the forecast period, 2024-2029, Global Therapeutic Antibody is expected to expand at a CAGR of 11.2%. Advances in bioprocessing and manufacturing technologies are ongoing. These improvements can lead to increased efficiency, reduced costs, and a more sustainable production of therapeutic antibodies.
According to the World Health Organization (WHO), Noncommunicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. The rising incidence of chronic diseases, including cancer, autoimmune disorders, and inflammatory conditions, is a major driver for the therapeutic antibody market. Antibodies can be designed to target specific molecules involved in these diseases, providing targeted and effective treatments.
The COVID-19 pandemic has underscored the importance of therapeutic antibodies in infectious disease management. Antibodies have been developed and authorized for emergency use in the treatment of COVID-19, highlighting their potential in addressing global health challenges. The urgent need for effective treatments during the pandemic has led to expedited development, clinical trials, and regulatory approval processes. This has demonstrated the agility of the industry and regulatory agencies in responding to emerging health crises.
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Advances in precision medicine and the discovery of cancer biomarkers contribute to the development of personalized antibody therapies. Identifying specific molecular targets allows for the design of antibodies tailored to individual patients or specific cancer subtypes.
Researchers continue to engineer antibodies with improved specificity and affinity for their target antigens. This can lead to more effective and precise therapeutic interventions with fewer side effects. Development of novel antibody formats, such as nanobodies, bispecific antibodies, and multispecific antibodies, to expand the therapeutic capabilities and applications.
The utilization of humanized sources in the global therapeutic antibody market offers a range of opportunities, from improving safety and efficacy to expanding target portfolios and enabling advanced engineering approaches. These opportunities contribute to the continued growth and diversification of antibody-based therapies. Advances in antibody engineering have allowed the modification of antibody structures for improved therapeutic properties. Techniques include humanization to reduce immunogenicity, affinity maturation for enhanced binding to target antigens, and isotype switching for optimized effector functions.
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: Therapeutic Antibody in Pipeline
Table A3: United States Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A4: United States Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A5: United States Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A6: United States Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A7: United States Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A8: United States Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A9: Canada Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A10: Canada Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A11: Canada Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A12: Canada Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A13: Canada Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A14: Canada Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A15: Rest of Americas Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A16: Rest of Americas Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A17: Rest of Americas Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A18: Rest of Americas Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A19: Rest of Americas Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A20: Rest of Americas Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A21: United Kingdom Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A22: United Kingdom Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A23: United Kingdom Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A24: United Kingdom Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A25: United Kingdom Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A26: United Kingdom Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A27: Germany Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A28: Germany Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A29: Germany Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A30: Germany Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A31: Germany Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A32: Germany Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A33: France Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A34: France Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A35: France Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A36: France Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A37: France Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A38: France Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A39: Spain Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A40: Spain Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A41: Spain Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A42: Spain Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A43: Spain Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A44: Spain Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A45: Rest of Europe Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A46: Rest of Europe Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A47: Rest of Europe Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A48: Rest of Europe Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A49: Rest of Europe Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A50: Rest of Europe Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A51: China Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A52: China Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A53: China Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A54: China Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A55: China Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A56: China Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A57: Japan Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A58: Japan Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A59: Japan Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A60: Japan Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A61: Japan Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A62: Japan Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A63: South Korea Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A64: South Korea Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A65: South Korea Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A66: South Korea Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A67: South Korea Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A68: South Korea Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A69: India Therapeutic Antibody Market, By Product Type, By Value, 2019-2022 (USD Billion)
Table A70: India Therapeutic Antibody Market, By Product Type, By Value, 2023-2029 (USD Billion)
Table A71: India Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A72: India Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A73: India Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A74: India Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A75: Rest of Asia-Pacific Therapeutic Antibody Market, By Product Type Industry, By Value, 2019-2022 (USD Billion)
Table A76: Rest of Asia-Pacific Therapeutic Antibody Market, By Product Type Industry, By Value, 2023-2029 (USD Billion)
Table A77: Rest of Asia-Pacific Therapeutic Antibody Market, By Source, By Value, 2019-2022 (USD Billion)
Table A78: Rest of Asia-Pacific Therapeutic Antibody Market, By Source, By Value, 2023-2029 (USD Billion)
Table A79: Rest of Asia-Pacific Therapeutic Antibody Market, By Application, By Value, 2019-2022 (USD Billion)
Table A80: Rest of Asia-Pacific Therapeutic Antibody Market, By Application, By Value, 2023-2029 (USD Billion)
Table A81: Roche Key Financials, 2020-2022
Table A82: Bristol-Myers Squibb Key Financials, 2020-2022
Table A83: AbbVie Inc. Key Company Financials, 2020-2022
Table A84: Merck & Co., Inc. Key Financials, 2020-2022
Table A85: Johnson & Johnson Key Financials, 2020-2022
Table A86: Novartis Key Company Financials, 2020-2022
Table A87: Regeneron Key Company Financials, 2020-2022
Table A88: Takeda Pharmaceuticals Key Financials, 2020-2022
Table A89: Amgen, Inc. Key Financials, 2020-2022
Table A90: Eli Lilly and Company Key Financials, 2020-2022